Table 3 RSV-related hospitalization risk

Palivizumab non-compliance (ref. compliance)

2.007 (1.392 - 2.894)

<0.001

Chronic lung disease

2.035 (1.262 - 3.281)

0.004

Congenital heart disease

1.24 (0.778 - 1.978)

0.366

33-36 wGA (ref. < 33 wGA)

0.983 (0.634 - 1.522)

0.937

Unknown wGA (ref. < 33 wGA)

1.966 (1.206 - 3.206)

0.007

Male gender (ref. female)

1.152 (0.841 - 1.578)

0.378

Geographic region – Northeast (ref. South)

0.813 (0.469 - 1.407)

0.459

Geographic region – Midwest (ref. South)

1.226 (0.854 - 1.759)

0.269

Geographic region – West (ref. South)

0.862 (0.526 - 1.414)

0.557

Index year – 2004 (ref. 2003)

1.027 (0.618 - 1.706)

0.919

Index year – 2005 (ref. 2003)

0.893 (0.528 - 1.513)

0.675

Index year – 2006 (ref. 2003)

0.724 (0.415 - 1.262)

0.254

Index year – 2007 (ref. 2003)

0.827 (0.463 - 1.476)

0.520

Index year – 2008 (ref. 2003)

0.922 (0.534 - 1.591)

0.769

Birth number – multiple birth (ref. single birth)

0.418 (0.267 - 0.655)

<0.001

Birth number – unknown (ref. single birth)

0.656 (0.313 - 1.373)

0.263

Pre-index palivizumab use

0.507 (0.276 - 0.933)

0.029

NICU hospitalization at birth (ref. no NICU)

1.354 (0.807 - 2.274)

0.251

Unknown NICU hospitalization at birth (ref. no NICU)

0.875 (0.312 - 2.457)

0.800

Pre-index ambulatory visit

0.677 (0.162 - 2.827)

0.593

Pre-index emergency department visit

1.746 (1.231 - 2.477)

0.002

Pre-index inpatient hospitalization

1.258 (0.387 - 4.085)

0.703

Pre-index RSV-related hospitalization

3.059 (1.574 - 5.942)

0.001

Any pre-index comorbid condition

2.003 (1.411 - 2.843)

<0.001

Low birth weight (<2500 g)

0.906 (0.598 - 1.373)

0.643

Birth month: May (ref. Sept)

1.019 (0.587 - 1.769)

0.947

Birth month: June (ref. Sept)

0.7 (0.394 - 1.244)

0.224

Birth month: July (ref. Sept)

0.794 (0.456 - 1.384)

0.416

Birth month: August (ref. Sept)

0.713 (0.405 - 1.256)

0.242